Ocular mucous membrane pemphigoid: a review

Taurone, S.; Spoletini, M.*; Ralli, M. ✉; Gobbi, P.; Artico, M.; Imre, L. [Imre, László (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K); Czakò, C. [Czakó, Cecilia Nóra (szemészet), szerző] Szemészeti Klinika (SE / AOK / K); Kovàcs, I. [Kovács, Illés (Szemészet), szerző] Szemészeti Klinika (SE / AOK / K); Greco, A.**; Micera, A.

Angol nyelvű Tudományos Összefoglaló cikk (Folyóiratcikk)
Megjelent: IMMUNOLOGIC RESEARCH 0257-277X 67 (2-3) pp. 280-289 2019
  • SJR Scopus - Immunology: Q3
Azonosítók
Ocular mucous membrane pemphigoid (MMP) is a rare, immuno-mediated chronic progressive condition of the conjunctiva characterized by blisters developing from sub-epithelial tissue through disruption of the adhesions between the conjunctival epithelium and the sub-epithelium. Patients with ocular MMP, in many cases, develop profound conjunctival scarring and visual impairment. Furthermore, ocular MMP may lead to a progressive secondary corneal vascularization and to corneal opacification. Ocular MMP is difficult to diagnose during the initial stages because of false negatives during biopsy and variability in the clinical presentation. Most of the current pharmacological treatments aim to control the inflammatory response to reduce the progressive tissue remodeling which leads to the formation of a fibrotic scar. The course and prognosis of ocular MMP depend on the severity and progression of the disease after systemic immunomodulatory therapy. The aim of this review is to provide a comprehensive analysis of the current literature on established and emerging concepts in ocular MMP, with special attention to its clinical presentation, diagnosis, treatment, and pathogenic mechanisms, including the role of some cytokines and growth factors in the development of the disease. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
2021-03-05 03:10